Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase ...
Micromet announced updated results from a Phase 2 trial of blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). This multi-center ...
German biotech company Micromet says MT103 proves effective in treating non-Hodgkin's lymphoma. Seven patients who had failed at least three conventional treatments showed signs of recovery after ...
GAITHERSBURG, Md. and CARLSBAD, Calif., Aug. 21, 2006 (PRIMEZONE) -- MedImmune, Inc. (Nasdaq:MEDI) and Micromet, Inc. (Nasdaq:MITI) today announced that MedImmune has ...
Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results